Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$23.33 USD
+2.71 (13.14%)
Updated May 14, 2024 04:00 PM ET
After-Market: $23.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SAVA 23.33 +2.71(13.14%)
Will SAVA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SAVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SAVA
Brian's Big Idea on Low Priced Stocks
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
SAVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
Other News for SAVA
Cassava Sciences call volume above normal and directionally bullish
Cassava Sciences Progresses in Phase 3 Trials, Secures Strong Cash Position: A Buy Rating Justified
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
Cassava Sciences (NASDAQ:SAVA): Cracking Alzheimer’s or Succumbing to Short Sellers?
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024